Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

Without frequent measurement of vision to monitor disease progression some people may be
under-treated, while others over-treated. Under-treatment can lead to severe and irreversible
disease progression and associated loss of vision. Over-treatment is expensive, uncomfortable
and potentially increases the risk of complications. A self-monitoring device such as
DigiSight can help subjects keep close control of their treatment, but alleviate the burden
of in office monitoring visits. A decreased number of office visits in combination with the
home self-monitoring may provide an effective alternative dosing regimen, allowing the
physician and subject to closely track the disease progression and treatment effect without
the demands of monthly or frequent visits to the office.

Inclusion Criteria:

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age > 50 years

- Choroidal neovascular membrane (CNV) secondary to AMD, as confirmed by the patient's
medical history and a documented diagnosis of CNV

- The study eye must have received at least 3 anti-Vascular endothelial growth factor
(VEGF) treatments prior to the screening visit, with at least 2 anti-VEGF treatments
over the preceding 3 months.

- Best-corrected visual acuity (BCVA) of 20/32 to 20/200 Snellen equivalent in the study
eye

- Noted presence of intra- or sub-retinal fluid on OCT in the study eye

- Adequate pupillary dilation to permit thorough ocular examination and testing in both
eyes

- Proficiency in using the DigiSight SightBook™ mobile vision assessment tool on
study-supplied Apple iPad or iPod device

Exclusion Criteria:

- CNV in the study eye due to any reason other than AMD

- Active uncontrolled glaucoma

- Had any intraocular surgeries in the study eye within 3 months of enrollment or are
known or likely candidates for intraocular surgery (including cataract surgery) in the
study eye within 1 year of enrollment

- Acute or chronic ocular or periocular infection in the study eye, uveitis or ocular
inflammation in the study eye

- Received Photo Dynamic Therapy (PDT) in the study eye within 60 days, or laser
photocoagulation within 14 days prior to screening

- Currently using any periocular or intravitreal steroids within 3 months prior to
screening (study eye)

- Unstable or severe cardiovascular disease, e.g., congestive heart failure (New York
Heart Association Functional class III/IV), myocardial infarction within 6 months,
ventricular tachyarrhythmias requiring ongoing treatment, unstable angina, or critical
limb ischemia

- Poorly controlled diabetes

- Cerebrovascular disease within 12 months prior to Screening

- Dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease)

- Received any investigational product within 30 days prior to Screening

- Inability to properly use the SightBook™ app